AIDS Therapy

Data shows reduced opportunistic infections in AIDS patients treated with HE2000

Published in AIDS Weekly, July 21st, 2003

Hollis-Eden Pharmaceuticals, Inc., (HEPH) announced additional data from a phase II clinical trial conducted in South Africa in late-stage HIV patients who have progressed to AIDS (average starting CD4 count for patients in the trial was less than 50).

Patients in this study treated with IMMUNITIN (HE2000), the company's lead investigational compound for infectious disease, experienced a statistically significant reduction in the total number of all opportunistic infections (OIs) over the 13-month study period when compared to patients receiving placebo.

There were 25 evaluable patients in the study who were dosed once a day with either IMMUNITIN or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-07-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry